The efficacy and safety of first-line pembrolizumab (with or without chemotherapy) was subsequently compared with chemotherapy alone in patients with PD-L1–positive (combined positive score [CPS] ≥1) advanced GC/GEJC in the phase 3 KEYNOTE-062 trial (14). This evidence concerns the gene CD274 and gastric cancer.